Breast Cancer Public- Private Trastuzumab Access Program in Ghana

Click image below to read about the program.

Further to the Breast Cancer Patient journey research and publication, the findings were established that the only way to ensure access to standard of care immunotherapy for HER2+ Breast cancer patients was via a public- private MoU wherein the patients get end to end treatment subsidized treatment subsidized and paid for by the National Health Insurance Authority (NHIA) in Ghana (click image above to read the media publication details of the MoU).

Implementation of such an MoU requires governance around patient onboarding, diagnostics and vetting , data capture of all phases of the treatment, automated demand planning of the drug supply for all hospitals engaged in the MoU, patient treatment weekly schedule for physicians to plan, patient follow up by a NGO, automation of treatment protocol in the platform and geocoding the data to visually see how far the patients are traveling to their respective hospitals (this helps referrals to the most appropriate Centre for treatment).

Impact:

The program went live in 2019 and by 2023, there were hundreds of breast cancer HER2+ patients who were being managed in the Inshira platform successfully with access to all 18 cycles of Trastuzumab. The platform centrally captures data in all 5 hospitals namely Cape Coast, Accra, Tamale, Kumasi and Ho.